Tumor size combined with staging systems for thymoma recurrence prediction: A 28-year experience

Hao-Yun Liu; Ya-Fang Liu; Yi-Chen Chang; Hou-Chang Chiu; Jiann-Horng Yeh

doi:10.1016/j.sopen.2023.10.005

Tumor size combined with staging systems for thymoma recurrence prediction: A 28-year experience

Surg Open Sci. 2023 Oct 30:16:157-161. doi: 10.1016/j.sopen.2023.10.005. eCollection 2023 Dec.

Authors

Hao-Yun Liu^{1

2}, Ya-Fang Liu³, Yi-Chen Chang¹, Hou-Chang Chiu⁴, Jiann-Horng Yeh^{5

6}

Affiliations

¹ Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
² National Taiwan University College of Medicine, Taiwan.
³ Department of Research, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
⁴ Department of Neurology, Shuang-Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
⁵ Deputy Superintendent, Education and Research, Shin Kong Wu Ho-Su Memorial Hospital, Taiwan.
⁶ College of Medicine, Fu Jen Catholic University, Taipei, Taiwan.

Abstract

Background: We evaluated a new thymoma prognosis prediction model by combining current staging systems with tumor size.

Methods: The clinical records of thymoma patients in a single center between January 1993 and December 2021 were collected, and data on tumor size and stage and recurrence-free survival (RFS) was obtained. The prediction model was designed by combining staging with tumor size.

Results: During 28 years, 219 thymoma patients were enrolled. Twenty-seven patients had a median RFS of 8.2 years. Further, 153 patients were categorized into limited stage and 66 patients into advanced stage. The RFS was statistically different between these two groups (P = 0.022). The largest area under the curve (AUC) of receiver operating characteristic (ROC) was the dividing group as 5 cm (AUC: 0.804).

Conclusions: Combining tumor staging and size improves thymoma recurrence prediction. Patients with advanced stage and tumor size >5 cm may show a poor prognosis.

Keywords: Predict model; Recurrence; Stage; Thymoma; Tumor size.